These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Cole JC; Sumnall HR; O'Shea E; Marsden CA Psychopharmacology (Berl); 2003 Apr; 166(4):383-90. PubMed ID: 12601504 [TBL] [Abstract][Full Text] [Related]
3. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661 [TBL] [Abstract][Full Text] [Related]
4. Effects of risperidone on the acquisition and reinstatement of the conditioned place preference induced by MDMA. Roger-Sánchez C; Rodríguez-Arias M; Miñarro J; Aguilar MA Brain Res Bull; 2013 Sep; 98():36-43. PubMed ID: 23892054 [TBL] [Abstract][Full Text] [Related]
5. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Buchert R; Thomasius R; Wilke F; Petersen K; Nebeling B; Obrocki J; Schulze O; Schmidt U; Clausen M Am J Psychiatry; 2004 Jul; 161(7):1181-9. PubMed ID: 15229049 [TBL] [Abstract][Full Text] [Related]
6. Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors. Ponzoni L; Braida D; Sala M Psychopharmacology (Berl); 2016 Aug; 233(15-16):3031-9. PubMed ID: 27318987 [TBL] [Abstract][Full Text] [Related]
7. A genetic deletion of the serotonin transporter differentially influences the behavioural effects of MDMA. Pettie M; Oakly A; Harper DN; Ellenbroek BA J Psychopharmacol; 2019 Mar; 33(3):355-363. PubMed ID: 30665313 [TBL] [Abstract][Full Text] [Related]
8. Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice. Murnane KS; Murai N; Howell LL; Fantegrossi WE J Pharmacol Exp Ther; 2009 Nov; 331(2):717-23. PubMed ID: 19684254 [TBL] [Abstract][Full Text] [Related]
9. Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Robledo P; Trigo JM; Panayi F; de la Torre R; Maldonado R Psychopharmacology (Berl); 2007 Dec; 195(2):255-64. PubMed ID: 17684733 [TBL] [Abstract][Full Text] [Related]
11. Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Colado MI; O'Shea E; Green AR Psychopharmacology (Berl); 2004 May; 173(3-4):249-63. PubMed ID: 15083264 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters. Pifl C; Nagy G; Berényi S; Kattinger A; Reither H; Antus S J Pharmacol Exp Ther; 2005 Jul; 314(1):346-54. PubMed ID: 15831439 [TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Erritzoe D; Frokjaer VG; Holst KK; Christoffersen M; Johansen SS; Svarer C; Madsen J; Rasmussen PM; Ramsøy T; Jernigan TL; Knudsen GM Arch Gen Psychiatry; 2011 Jun; 68(6):562-76. PubMed ID: 21646575 [TBL] [Abstract][Full Text] [Related]
14. Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') using a drug discrimination paradigm in the rat. Broadbear JH; Tunstall B; Beringer K Addict Biol; 2011 Apr; 16(2):202-14. PubMed ID: 21070509 [TBL] [Abstract][Full Text] [Related]
15. Synaptotagmin I and IV are differentially regulated in the brain by the recreational drug 3,4-methylenedioxymethamphetamine (MDMA). Peng W; Premkumar A; Mossner R; Fukuda M; Lesch KP; Simantov R Brain Res Mol Brain Res; 2002 Dec; 108(1-2):94-101. PubMed ID: 12480182 [TBL] [Abstract][Full Text] [Related]
16. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Wang X; Baumann MH; Xu H; Rothman RB Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556 [TBL] [Abstract][Full Text] [Related]
17. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479 [TBL] [Abstract][Full Text] [Related]
18. Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents. Gatch MB; Dolan SB; Forster MJ Behav Pharmacol; 2016 Sep; 27(6):497-505. PubMed ID: 27028902 [TBL] [Abstract][Full Text] [Related]
19. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Clemens KJ; McGregor IS; Hunt GE; Cornish JL Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831 [TBL] [Abstract][Full Text] [Related]
20. Long-lasting behavioral sensitization to psychostimulants following p-chloroamphetamine-induced neurotoxicity in mice. Itzhak Y; Achat-Mendes CN; Ali SF; Anderson KL Neuropharmacology; 2004 Jan; 46(1):74-84. PubMed ID: 14654099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]